Certara (NASDAQ:CERT) Trading 10.4% Higher – Time to Buy?

Certara, Inc. (NASDAQ:CERT) shares were up 10.4% during trading on Wednesday . The company traded as high as $11.86 and last traded at $11.86. Approximately 208,804 shares were traded during trading, a decline of 74% from the average daily volume of 795,817 shares. The stock had previously closed at $10.74.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on CERT shares. UBS Group upgraded shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a research note on Friday, September 27th. Robert W. Baird reduced their price objective on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Finally, Barclays decreased their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Six research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $15.92.

Certara Trading Down 1.7 %

The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The business’s 50 day simple moving average is $10.90 and its 200 day simple moving average is $11.95. The stock has a market cap of $1.89 billion, a P/E ratio of -58.80, a PEG ratio of 4.55 and a beta of 1.52.

Certara (NASDAQ:CERT) last posted its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.11 by $0.02. The business had revenue of $94.80 million during the quarter, compared to the consensus estimate of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. Certara’s revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the company earned $0.06 EPS. On average, analysts expect that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Certara

Several institutional investors and hedge funds have recently made changes to their positions in CERT. Brown Brothers Harriman & Co. bought a new position in Certara during the 3rd quarter valued at about $27,292,000. Wasatch Advisors LP raised its stake in shares of Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company’s stock valued at $105,577,000 after acquiring an additional 1,651,076 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock valued at $45,691,000 after acquiring an additional 1,128,006 shares during the last quarter. Daventry Group LP boosted its holdings in shares of Certara by 153.0% in the 2nd quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after acquiring an additional 791,405 shares in the last quarter. Finally, Glenmede Trust Co. NA grew its position in Certara by 78.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 1,206,069 shares of the company’s stock worth $14,123,000 after acquiring an additional 530,598 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.